Creative Biomart Blog

Sun, 2025/09/07

Glucose Helps Recharge Anti-Cancer T Cells

Glycosphingolipid Synthesis is the Key! This study clarifies for the first time that glucose-dependent glycosphingolipid synthesis serves as a "metabolic checkpoint" for CD8⁺ T cells to exert their anti-cancer functions. When this pathway is blocked, T cells face the dilemma of being "armed but without ammunition"—able to infiltrate tumors yet incapable of effectively killing cancer cells. Fig1. Graphical abstract The rise of tumor immunotherapy has brought new hope to cancer patients, but most still face the challenge of insufficient efficacy. Among them, CD8⁺ T cells, as the "main fo

Sat, 2025/08/23

Unveiling the Activation Mechanism of Steroid Hormone Receptors Through Structural Proteomics

This new study provides the first detailed revelation of the structure of this steroid hormone receptor complex. Imagine a drug that could block cancer without side effects or risks. This future might be closer due to a new study led by Dr. Raj Kumar, the Chair of the Department of Pharmaceutical and Biomedical Sciences at the University of Toledo College of Pharmacy and Pharmaceutical Sciences. The findings are published in the journal Nature Communications. The Kumar laboratory has been focused on studying steroid hormone receptors (SHRs), which are among the most frequently targeted protein

Sat, 2025/08/23

Dual Payload ADCs-Ushering in a New Wave

Dual Payload ADCs aim to enhance drug activity, produce synergistic effects, improve therapeutic efficacy, expand indications, and overcome resistance challenges by simultaneously attaching two payloads with different mechanisms (or different linker forms of the same payload) to a single antibody, allowing flexible modulation of the total drug-to-antibody ratio (DAR). Currently, two dual payload ADCs have entered clinical trials for cancer treatment, with dozens of candidates in preclinical development. The activity in this field is evident from the dynamic financing landscape: Startup Callio

Sat, 2025/08/23

Clinical research highlights in the second half of 2025: Eli Lilly, Sanofi, Akeso, Roche, etc.

In the second half of 2025, several pivotal clinical research results are set to be announced, which may redefine treatment paradigms: from Eli Lilly's GLP-1 small molecule orforglipron, potentially reshaping the oral weight loss market, to Sanofi's immune up-and-comer amlitelimab, taking up the baton from Dupixent; from Akeso's challenge to PD-1 giant Keytruda's OS finale, to Roche's efforts to overcome BTK inhibitor challenges in multiple sclerosis research... These studies not only pertain to the rise and fall of major pharmaceutical companies' pipelines, stirring market expectations for ne

Sat, 2025/08/23

A WNT-free culture medium for head and neck tumor organoids accurately replicates tumor characteristics

This study established a patient-derived organoid model of head and neck squamous cell carcinoma (HNSCC) using a WNT-free culture medium. The organoids closely mimic the primary tumor characteristics and can predict the patients' responses to chemoradiation therapy, thus providing a powerful tool for personalized treatment. Head and neck squamous cell carcinoma (HNSCC) is a prevalent and lethal malignant tumor with significant treatment-related toxicity. According to the American Cancer Society, there will be over 66,000 new cases of oral, pharyngeal, and laryngeal cancer in the United States

Sun, 2025/07/13

Partial CXCR4 agonists can block the generation of immunosuppressive neutrophils

The chemokine receptor CXCR4 partial agonist TFF2-MSA can reduce the generation of immunosuppressive neutrophils at the source, thereby synergizing with PD-1 inhibitors to suppress primary tumor growth and distant metastasis, and prolong the survival of gastric cancer mouse models. We witnessed the power of tumor's "long - arm jurisdiction" last month. Early last month, researchers from the Netherlands Cancer Institute found that breast cancer's remodeling of neutrophils starts with hematopoiesis in the bone marrow, leading to the generation of numerous immunosuppressive neutrophils, suppressi

Sun, 2025/07/13

New research reveals that the interaction between paxillin and FAK may influence cancer treatment resistance

This study adds important new details to a cell protein network that is difficult to characterize. Dr. Salgia and his team focused on paxillin, a protein that allows cells to adapt based on environmental changes. This helps cancer cells evolve and evade detection while triggering resistance to treatment. In a new study, an international research team led by scientists from City of Hope provided the most comprehensive elucidation to date of an elusive target in cancer treatment. They highlighted a complex signaling process involving paxillin that may be sensitive to treatment, even though the p

Sun, 2025/07/13

Advances in CAR-T Cell Therapy Research (I)

CAR-T (Chimeric Antigen Receptor T-Cell Immunotherapy) is a novel cell-based therapy that has been around for several years. It has only recently been refined and applied in clinical settings. This therapy has shown remarkable efficacy in treating acute leukemia and non-Hodgkin lymphoma and is considered one of the most promising cancer treatment approaches. Like all technologies, CAR-T has undergone a long evolutionary process, during which it has gradually matured. The crux of this new therapeutic strategy lies in an artificial receptor called the chimeric antigen receptor (CAR), which can i